Eintrag weiter verarbeiten
Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia
Gespeichert in:
| Zeitschriftentitel: | Lupus |
|---|---|
| Personen und Körperschaften: | , , , , , , |
| In: | Lupus, 28, 2019, 9, S. 1082-1090 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
SAGE Publications
|
| Schlagwörter: |
| author_facet |
Almalki, A H Alrowaie, F A Alhozali, H M Almalki, N K Alsubei, A I Alturki, M S Sadagah, L F Almalki, A H Alrowaie, F A Alhozali, H M Almalki, N K Alsubei, A I Alturki, M S Sadagah, L F |
|---|---|
| author |
Almalki, A H Alrowaie, F A Alhozali, H M Almalki, N K Alsubei, A I Alturki, M S Sadagah, L F |
| spellingShingle |
Almalki, A H Alrowaie, F A Alhozali, H M Almalki, N K Alsubei, A I Alturki, M S Sadagah, L F Lupus Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia Rheumatology |
| author_sort |
almalki, a h |
| spelling |
Almalki, A H Alrowaie, F A Alhozali, H M Almalki, N K Alsubei, A I Alturki, M S Sadagah, L F 0961-2033 1477-0962 SAGE Publications Rheumatology http://dx.doi.org/10.1177/0961203319860584 <jats:sec><jats:title>Background</jats:title><jats:p>Few data are available about the rate of short-term remission and its impact on the long-term outcomes of proliferative lupus nephritis in the Middle East.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>An observational study was carried out involving 96 adult patients with biopsy-proven focal or diffuse proliferative lupus nephritis (PLN) from four different hospitals. Data on induction, remission and long-term outcomes were collected and analyzed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Among the 96 patients with biopsy-proven PLN (median age 27 (IQR: 21,34) years, 85% women and median duration of systemic lupus erythematosus (SLE) prior to diagnosis 27 (IQR: 11, 55) months), 67% developed remission at 6 months (proportion 0.67; 95% CI 0.57, 0.76). Mycophenolate mofetil (MMF) was used in 45/96 (47%), CYC in 41/95 (43%) and other agents in 10/96 (10%). The choice of MMF as induction agent has increased in recent years. Among baseline characteristics, only histologic activity was found to have a significant association with remission, with active lesions more likely to remit than active/chronic and chronic lesions (AOR 6.5, 95% CI 1.44–29.39, p = 0.015). Based on Kaplan–Meier analysis, the 5-year renal survival rate without doubling serum creatinine was 73.8%. Compared to patients with complete remission, lower long-term renal survival rates were observed in patients with no remission (89.7 versus 43%, p = 0.001) and partial remission (89.7 versus 77.6%, p = 0.256). The cumulative rate of doubling serum creatinine, dialysis, relapse and death was 23%, 11%, 10% and 5%, respectively, at 48-month median follow up.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Approximately two-thirds of patients with PLN develop remission in response to standard induction therapy. Remission was negatively associated with the presence of chronic changes in renal biopsy. Overall, MMF is the most commonly used agent to induce remission; however, with more severe disease CYC, is used more frequently. PLN is associated with significant long-term renal outcomes including a 26% cumulative rate of doubling of serum creatinine at 5 years. Initial remission predicts this long-term renal survival.</jats:p></jats:sec> Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia Lupus |
| doi_str_mv |
10.1177/0961203319860584 |
| facet_avail |
Online |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE3Ny8wOTYxMjAzMzE5ODYwNTg0 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE3Ny8wOTYxMjAzMzE5ODYwNTg0 |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
SAGE Publications, 2019 |
| imprint_str_mv |
SAGE Publications, 2019 |
| issn |
0961-2033 1477-0962 |
| issn_str_mv |
0961-2033 1477-0962 |
| language |
English |
| mega_collection |
SAGE Publications (CrossRef) |
| match_str |
almalki2019remissionandlongtermoutcomesofproliferativelupusnephritisretrospectivestudyof96patientsfromsaudiarabia |
| publishDateSort |
2019 |
| publisher |
SAGE Publications |
| recordtype |
ai |
| record_format |
ai |
| series |
Lupus |
| source_id |
49 |
| title |
Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia |
| title_unstemmed |
Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia |
| title_full |
Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia |
| title_fullStr |
Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia |
| title_full_unstemmed |
Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia |
| title_short |
Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia |
| title_sort |
remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from saudi arabia |
| topic |
Rheumatology |
| url |
http://dx.doi.org/10.1177/0961203319860584 |
| publishDate |
2019 |
| physical |
1082-1090 |
| description |
<jats:sec><jats:title>Background</jats:title><jats:p>Few data are available about the rate of short-term remission and its impact on the long-term outcomes of proliferative lupus nephritis in the Middle East.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>An observational study was carried out involving 96 adult patients with biopsy-proven focal or diffuse proliferative lupus nephritis (PLN) from four different hospitals. Data on induction, remission and long-term outcomes were collected and analyzed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Among the 96 patients with biopsy-proven PLN (median age 27 (IQR: 21,34) years, 85% women and median duration of systemic lupus erythematosus (SLE) prior to diagnosis 27 (IQR: 11, 55) months), 67% developed remission at 6 months (proportion 0.67; 95% CI 0.57, 0.76). Mycophenolate mofetil (MMF) was used in 45/96 (47%), CYC in 41/95 (43%) and other agents in 10/96 (10%). The choice of MMF as induction agent has increased in recent years. Among baseline characteristics, only histologic activity was found to have a significant association with remission, with active lesions more likely to remit than active/chronic and chronic lesions (AOR 6.5, 95% CI 1.44–29.39, p = 0.015). Based on Kaplan–Meier analysis, the 5-year renal survival rate without doubling serum creatinine was 73.8%. Compared to patients with complete remission, lower long-term renal survival rates were observed in patients with no remission (89.7 versus 43%, p = 0.001) and partial remission (89.7 versus 77.6%, p = 0.256). The cumulative rate of doubling serum creatinine, dialysis, relapse and death was 23%, 11%, 10% and 5%, respectively, at 48-month median follow up.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Approximately two-thirds of patients with PLN develop remission in response to standard induction therapy. Remission was negatively associated with the presence of chronic changes in renal biopsy. Overall, MMF is the most commonly used agent to induce remission; however, with more severe disease CYC, is used more frequently. PLN is associated with significant long-term renal outcomes including a 26% cumulative rate of doubling of serum creatinine at 5 years. Initial remission predicts this long-term renal survival.</jats:p></jats:sec> |
| container_issue |
9 |
| container_start_page |
1082 |
| container_title |
Lupus |
| container_volume |
28 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792331165868228608 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T13:36:23.857Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Remission+and+long-term+outcomes+of+proliferative+lupus+nephritis%3A+retrospective+study+of+96+patients+from+Saudi+Arabia&rft.date=2019-08-01&genre=article&issn=1477-0962&volume=28&issue=9&spage=1082&epage=1090&pages=1082-1090&jtitle=Lupus&atitle=Remission+and+long-term+outcomes+of+proliferative+lupus+nephritis%3A+retrospective+study+of+96+patients+from+Saudi+Arabia&aulast=Sadagah&aufirst=L+F&rft_id=info%3Adoi%2F10.1177%2F0961203319860584&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792331165868228608 |
| author | Almalki, A H, Alrowaie, F A, Alhozali, H M, Almalki, N K, Alsubei, A I, Alturki, M S, Sadagah, L F |
| author_facet | Almalki, A H, Alrowaie, F A, Alhozali, H M, Almalki, N K, Alsubei, A I, Alturki, M S, Sadagah, L F, Almalki, A H, Alrowaie, F A, Alhozali, H M, Almalki, N K, Alsubei, A I, Alturki, M S, Sadagah, L F |
| author_sort | almalki, a h |
| container_issue | 9 |
| container_start_page | 1082 |
| container_title | Lupus |
| container_volume | 28 |
| description | <jats:sec><jats:title>Background</jats:title><jats:p>Few data are available about the rate of short-term remission and its impact on the long-term outcomes of proliferative lupus nephritis in the Middle East.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>An observational study was carried out involving 96 adult patients with biopsy-proven focal or diffuse proliferative lupus nephritis (PLN) from four different hospitals. Data on induction, remission and long-term outcomes were collected and analyzed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Among the 96 patients with biopsy-proven PLN (median age 27 (IQR: 21,34) years, 85% women and median duration of systemic lupus erythematosus (SLE) prior to diagnosis 27 (IQR: 11, 55) months), 67% developed remission at 6 months (proportion 0.67; 95% CI 0.57, 0.76). Mycophenolate mofetil (MMF) was used in 45/96 (47%), CYC in 41/95 (43%) and other agents in 10/96 (10%). The choice of MMF as induction agent has increased in recent years. Among baseline characteristics, only histologic activity was found to have a significant association with remission, with active lesions more likely to remit than active/chronic and chronic lesions (AOR 6.5, 95% CI 1.44–29.39, p = 0.015). Based on Kaplan–Meier analysis, the 5-year renal survival rate without doubling serum creatinine was 73.8%. Compared to patients with complete remission, lower long-term renal survival rates were observed in patients with no remission (89.7 versus 43%, p = 0.001) and partial remission (89.7 versus 77.6%, p = 0.256). The cumulative rate of doubling serum creatinine, dialysis, relapse and death was 23%, 11%, 10% and 5%, respectively, at 48-month median follow up.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Approximately two-thirds of patients with PLN develop remission in response to standard induction therapy. Remission was negatively associated with the presence of chronic changes in renal biopsy. Overall, MMF is the most commonly used agent to induce remission; however, with more severe disease CYC, is used more frequently. PLN is associated with significant long-term renal outcomes including a 26% cumulative rate of doubling of serum creatinine at 5 years. Initial remission predicts this long-term renal survival.</jats:p></jats:sec> |
| doi_str_mv | 10.1177/0961203319860584 |
| facet_avail | Online |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE3Ny8wOTYxMjAzMzE5ODYwNTg0 |
| imprint | SAGE Publications, 2019 |
| imprint_str_mv | SAGE Publications, 2019 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0961-2033, 1477-0962 |
| issn_str_mv | 0961-2033, 1477-0962 |
| language | English |
| last_indexed | 2024-03-01T13:36:23.857Z |
| match_str | almalki2019remissionandlongtermoutcomesofproliferativelupusnephritisretrospectivestudyof96patientsfromsaudiarabia |
| mega_collection | SAGE Publications (CrossRef) |
| physical | 1082-1090 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | SAGE Publications |
| record_format | ai |
| recordtype | ai |
| series | Lupus |
| source_id | 49 |
| spelling | Almalki, A H Alrowaie, F A Alhozali, H M Almalki, N K Alsubei, A I Alturki, M S Sadagah, L F 0961-2033 1477-0962 SAGE Publications Rheumatology http://dx.doi.org/10.1177/0961203319860584 <jats:sec><jats:title>Background</jats:title><jats:p>Few data are available about the rate of short-term remission and its impact on the long-term outcomes of proliferative lupus nephritis in the Middle East.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>An observational study was carried out involving 96 adult patients with biopsy-proven focal or diffuse proliferative lupus nephritis (PLN) from four different hospitals. Data on induction, remission and long-term outcomes were collected and analyzed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Among the 96 patients with biopsy-proven PLN (median age 27 (IQR: 21,34) years, 85% women and median duration of systemic lupus erythematosus (SLE) prior to diagnosis 27 (IQR: 11, 55) months), 67% developed remission at 6 months (proportion 0.67; 95% CI 0.57, 0.76). Mycophenolate mofetil (MMF) was used in 45/96 (47%), CYC in 41/95 (43%) and other agents in 10/96 (10%). The choice of MMF as induction agent has increased in recent years. Among baseline characteristics, only histologic activity was found to have a significant association with remission, with active lesions more likely to remit than active/chronic and chronic lesions (AOR 6.5, 95% CI 1.44–29.39, p = 0.015). Based on Kaplan–Meier analysis, the 5-year renal survival rate without doubling serum creatinine was 73.8%. Compared to patients with complete remission, lower long-term renal survival rates were observed in patients with no remission (89.7 versus 43%, p = 0.001) and partial remission (89.7 versus 77.6%, p = 0.256). The cumulative rate of doubling serum creatinine, dialysis, relapse and death was 23%, 11%, 10% and 5%, respectively, at 48-month median follow up.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Approximately two-thirds of patients with PLN develop remission in response to standard induction therapy. Remission was negatively associated with the presence of chronic changes in renal biopsy. Overall, MMF is the most commonly used agent to induce remission; however, with more severe disease CYC, is used more frequently. PLN is associated with significant long-term renal outcomes including a 26% cumulative rate of doubling of serum creatinine at 5 years. Initial remission predicts this long-term renal survival.</jats:p></jats:sec> Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia Lupus |
| spellingShingle | Almalki, A H, Alrowaie, F A, Alhozali, H M, Almalki, N K, Alsubei, A I, Alturki, M S, Sadagah, L F, Lupus, Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia, Rheumatology |
| title | Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia |
| title_full | Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia |
| title_fullStr | Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia |
| title_full_unstemmed | Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia |
| title_short | Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia |
| title_sort | remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from saudi arabia |
| title_unstemmed | Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia |
| topic | Rheumatology |
| url | http://dx.doi.org/10.1177/0961203319860584 |